USPTO serial 79368363
I-BODY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- MCDOWELL, MATTHEW J
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with I-BODY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Cheryl L. Burbach
Cheryl L. Burbach Erise IP, P.A.7015 College Boulevard, Suite 700Overland Park, KS 66211United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical, biotechnology and medical preparations and substances for medical use or purposes, namely, pharmaceutical preparations for the treatment of fibrosis, cancer and other diseases, biological preparations for the treatment of fibrosis, cancer and other diseases; Pharmaceutical, biotechnology and medical preparations and substances for medical use or purposes, namely, prescription injectable pharmaceutical preparations for the treatment of fibrosis, cancer and other diseases, prescription injectable biological preparations for the treatment of fibrosis, cancer and other diseases, inhaled pharmaceutical preparations for the treatment of fibrosis, cancer and other diseases, inhaled biological preparations for the treatment of fibrosis, cancer and other diseases; diagnostic preparations and reagents for medical purposes; antibodies for medical purposes; antibody fragments for medical purposes; antibody fragments for combining with other chemicals, proteins and cells for medical or diagnostic purposes; antibody conjugates for medical purposes; immunological antibodies for medical use; monoclonal antibodies for medical diagnostic use; monoclonal antibodies for medical use; monoclonal antibodies for therapeutic purposes; preparations containing antibodies for use in medicine; proteins for medical use in binding antibodies; proteins for medical use in detecting antibodies; reagents for medical research use in the development of monoclonal antibodies for medical purposes; molecular targets for drug and vaccine development, all in the nature of biological reagents for medical research use; tagged antibodies for medical research and medical use; vaccines; vaccines against cancer viral or bacterial infection; vaccines for human use; vaccine adjuvants; diagnostic preparations, reagents, substances, products and testing materials for medical purposes, namely, for capturing, imaging, detecting, identifying or characterising protein and cell therapeutic candidates; reagents for use in diagnostic tests for medical purposes; reagents for medical research applications for medical diagnosis; biological tissue, namely, recombinant human protein production cell line for medical use or modified human cells for therapeutic use; biological tissue, namely recombinant human protein production cell line for modified human cells for therapeutic use; proteins for medical use in recombinant DNA technology; biological reagents for use in molecular biology for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 28, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 28, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 23, 2026 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jul 22, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 8, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 8, 2026 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jun 26, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 31, 2026 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Apr 28, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 28, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 28, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 28, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 28, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 28, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Oct 27, 2025 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Apr 24, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Apr 20, 2025 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Oct 12, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 25, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 25, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 13, 2024 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Sep 13, 2024 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Sep 13, 2024 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 22, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 22, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 22, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 19, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 29, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 29, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 12, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 11, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 30, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| May 2, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 28, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 27, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |